
No spam. Unsubscribe anytime.
HPLC Purity Analysis
B7-33
CAS: 1818415-56-3
Anti-fibrotic therapy (cardiac, pulmonary, hepatic) · Wound repair biology and scar reduction · RXFP1 biased agonism
B7-33 is a single-chain peptide agonist of relaxin family peptide receptor 1 (RXFP1) derived from the B-chain of human relaxin-2.
- Anti-fibrotic therapy (cardiac, pulmonary, hepatic)
- Wound repair biology and scar reduction
- RXFP1 biased agonism
- Skin rejuvenation and collagen remodeling
This product is intended for laboratory research purposes only. Not for human consumption. Handle with appropriate safety precautions.
Frequently Bought Together
Bacteriostatic Water
Required for reconstitution
Snap-8
Skin / Cosmetic
No spam. Unsubscribe anytime.
HPLC Purity Analysis
Specifications
How B7-33 Works
B7-33 is a single-chain peptide agonist of relaxin family peptide receptor 1 (RXFP1) derived from the B-chain of human relaxin-2. Unlike native relaxin (which requires a two-chain A-B structure), B7-33 consists solely of the B-chain with modifications that enable RXFP1 binding and activation. It selectively activates anti-fibrotic signaling pathways (pERK1/2) through RXFP1 without activating the cAMP pathway, making it a biased agonist. This promotes collagen remodeling, reduces fibrosis, and enhances wound repair biology.
Research Applications
Pricing
| Size | Per Vial | 10-Pack |
|---|---|---|
2mg | $45.00 | $450.00 |
10mgBest Value | $160.00 | $1600.00 |
10-pack pricing shown. Volume discounts for 50+ vials — contact us.
Certificate of Analysis
This COA is a representative sample. A batch-specific Certificate of Analysis with full HPLC chromatograms and mass spectrometry data is included with every order.
Research Use Only. This product is intended for laboratory research purposes only. Not for human consumption. Handle with appropriate safety precautions.
Related Peptides

Snap-8
Studied for SNARE complex modulation and expression line reduction

Matrixyl
Studied for collagen I/III synthesis and ECM remodeling
Up to 50% OffSemaglutide
Clinically studied for steady weight reduction — once weekly
Up to 60% OffTirzepatide
The most studied dual-agonist for weight reduction